India, May 2 -- Arvinas, Inc. (ARVN), together with Pfizer Inc. (PFE), announced that the U.S. FDA has approved VEPPANU for adult patients with estrogen receptor-positive (ER+)/HER2-negative, ESR1-mutated advanced or metastatic breast cancer, following disease progression after at least one line of endocrine therapy.
VEPPANU is the first FDA-approved PROteolysis TArgeting Chimera (PROTAC), a novel class of protein degrader therapies. This milestone represents Arvinas' first approved medicine and marks a significant advancement in targeted protein degradation technology.
The approval was supported by results from the pivotal Phase 3 VERITAC-2 trial, which compared VEPPANU to fulvestrant in patients with ESR1 mutations. VEPPANU reduced the ...